



**Omthera Contacts:**

Douglas Carr  
Financial Controller  
Omthera Pharmaceuticals  
908-741-4323  
DCarr@Omthera.com

**Omthera Media Relations:**

Eric Goldman  
Rx Communications Group  
917-322-2563  
[egoldman@rxir.com](mailto:egoldman@rxir.com)

**Omthera Pharmaceuticals, Inc. to Present at the 23<sup>rd</sup> Annual Piper Jaffray Health Care Conference**

**Bedminster, NJ, November 21, 2011** -- Omthera Pharmaceuticals, Inc., a privately-held emerging specialty pharmaceuticals company, announced today that Jerry Wisler, President and Chief Executive Officer, will present a company overview at the 23<sup>rd</sup> Annual Piper Jaffray Health Care Conference on Wednesday, November 30, 2011 at 4:30pm ET at The New York Palace hotel.

**About Omthera Pharmaceuticals, Inc.**

Founded in 2008, Omthera Pharmaceuticals, Inc. is a privately held, emerging specialty pharmaceuticals company focusing its efforts on the clinical development of new therapies for dyslipidemia. Led by a team of experts with exceptional experience in developing new therapies for lipid disorders, Omthera is dedicated to developing innovative therapies for the millions of patients who have elevated triglyceride levels and increased risk of cardiovascular disease. In March 2011, the Company initiated a pivotal Phase III clinical trial for its lead product candidate, Epanova™, an Omega-3 fatty acid compound in development as a triglyceride-lowering adjunct therapy to diet in patients with very high triglycerides ( $\geq 500$  mg/dL). In August, 2011, Omthera initiated a Phase III trial for Epanova in patients with high triglycerides ( $\geq 200$  mg/dL and  $\leq 500$  mg/dL) currently on statin therapy. For more information, please visit [www.omthera.com](http://www.omthera.com).

###